- Fulgent’s growth is going to come down this year, according to guidance which was issued just before the coronavirus hit the US in earnest.
- From competitors with more recent updates, the picture doesn’t seem to be too alarming, at least not yet.
- Fulgent remains a solid growth company, and investors can nibble at the shares on one of the downswings.
- The big unknown is of course by how much the coronavirus pandemic will reduce growth, as that situation can get worse.
Fulgent Genetics Is Fundamentally Sound
April 11th, 2020 · No Comments